Alfica Sehgal, Judo Bio CSO
October 7, 2024 07:00 AM EDT
R&D

Ju­do Bio launch­es with $100M for kid­ney-tar­get­ed siR­NA ther­a­pies

Ryan Cross

Senior Science Correspondent

The kid­ney hasn’t al­ways got­ten much love from ge­net­ic med­i­cine.
The or­gan is vi­tal to our health, but is of­ten viewed as a li­a­bil­i­ty for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Pfiz­er tar­get­ed by ac­tivist, fol­low­ing post-pan­dem­ic stum­bles — re­ports

Up­stream and CAMP4 tar­get $182M, $67M IPOs

FDA puts Kezar lu­pus tri­al on hold af­ter ear­li­er re­port of pa­tient deaths

Biotech's third quar­ter was rel­a­tive­ly bright — with a few caveats

EMA re­views hair loss prod­ucts fol­low­ing con­cerns about sui­ci­dal thoughts

WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port

A service from the Financial Times